MiRNA-145  ||| S:0 E:10 ||| NNP
Regulates  ||| S:10 E:20 ||| NNP
the  ||| S:20 E:24 ||| DT
Development  ||| S:24 E:36 ||| NNP
of  ||| S:36 E:39 ||| IN
Congenital  ||| S:39 E:50 ||| NNP
Heart  ||| S:50 E:56 ||| NNP
Disease  ||| S:56 E:64 ||| NNP
Through  ||| S:64 E:72 ||| NNP
Targeting  ||| S:72 E:82 ||| NNP
FXN  ||| S:82 E:86 ||| NNP
Congenital  ||| S:86 E:97 ||| NNP
heart  ||| S:97 E:103 ||| NN
disease  ||| S:103 E:111 ||| NN
( ||| S:111 E:112 ||| -LRB-
CHD ||| S:112 E:115 ||| NNP
)  ||| S:115 E:117 ||| -RRB-
is  ||| S:117 E:120 ||| VBZ
the  ||| S:120 E:124 ||| DT
leading  ||| S:124 E:132 ||| JJ
cause  ||| S:132 E:138 ||| NN
of  ||| S:138 E:141 ||| IN
death  ||| S:141 E:147 ||| NN
in  ||| S:147 E:150 ||| IN
infants  ||| S:150 E:158 ||| NNS
in  ||| S:158 E:161 ||| IN
the  ||| S:161 E:165 ||| DT
world ||| S:165 E:170 ||| NN
.  ||| S:170 E:172 ||| .
The  ||| S:172 E:176 ||| DT
study  ||| S:176 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
CHDs  ||| S:185 E:190 ||| NNP
has  ||| S:190 E:194 ||| VBZ
come  ||| S:194 E:199 ||| VBN
a  ||| S:199 E:201 ||| DT
long  ||| S:201 E:206 ||| JJ
way  ||| S:206 E:210 ||| NN
since  ||| S:210 E:216 ||| IN
their  ||| S:216 E:222 ||| PRP$
classification  ||| S:222 E:237 ||| NN
and  ||| S:237 E:241 ||| CC
description ||| S:241 E:252 ||| NN
.  ||| S:252 E:254 ||| .
Although  ||| S:254 E:263 ||| IN
transcriptional  ||| S:263 E:279 ||| JJ
programmes  ||| S:279 E:290 ||| NN
that  ||| S:290 E:295 ||| WDT
are  ||| S:295 E:299 ||| VBP
impaired  ||| S:299 E:308 ||| VBN
in  ||| S:308 E:311 ||| IN
individuals  ||| S:311 E:323 ||| NNS
with  ||| S:323 E:328 ||| IN
CHDs  ||| S:328 E:333 ||| NNS
are  ||| S:333 E:337 ||| VBP
being  ||| S:337 E:343 ||| VBG
identified ||| S:343 E:353 ||| VBN
,  ||| S:353 E:355 ||| ,
the  ||| S:355 E:359 ||| DT
mechanisms  ||| S:359 E:370 ||| NNS
of  ||| S:370 E:373 ||| IN
how  ||| S:373 E:377 ||| WRB
these  ||| S:377 E:383 ||| DT
deficiencies  ||| S:383 E:396 ||| NNS
translate  ||| S:396 E:406 ||| VBP
to  ||| S:406 E:409 ||| TO
a  ||| S:409 E:411 ||| DT
structural  ||| S:411 E:422 ||| JJ
defect  ||| S:422 E:429 ||| NNS
are  ||| S:429 E:433 ||| VBP
unknown ||| S:433 E:440 ||| JJ
.  ||| S:440 E:442 ||| .
In  ||| S:442 E:445 ||| IN
this  ||| S:445 E:450 ||| DT
study ||| S:450 E:455 ||| NN
,  ||| S:455 E:457 ||| ,
using  ||| S:457 E:463 ||| VBG
high-throughput  ||| S:463 E:479 ||| JJ
microarray  ||| S:479 E:490 ||| JJ
analysis  ||| S:490 E:499 ||| NN
and  ||| S:499 E:503 ||| CC
molecular  ||| S:503 E:513 ||| JJ
network  ||| S:513 E:521 ||| NN
analysis ||| S:521 E:529 ||| NN
,  ||| S:529 E:531 ||| ,
FXN  ||| S:531 E:535 ||| NNP
was  ||| S:535 E:539 ||| VBD
identified  ||| S:539 E:550 ||| VBN
to  ||| S:550 E:553 ||| TO
be  ||| S:553 E:556 ||| VB
the  ||| S:556 E:560 ||| DT
most  ||| S:560 E:565 ||| JJS
differentially  ||| S:565 E:580 ||| NN
expressed  ||| S:580 E:590 ||| VBD
key  ||| S:590 E:594 ||| JJ
gene  ||| S:594 E:599 ||| NN
in  ||| S:599 E:602 ||| IN
CHD ||| S:602 E:605 ||| NNP
.  ||| S:605 E:607 ||| .
By  ||| S:607 E:610 ||| IN
TargetScan  ||| S:610 E:621 ||| JJ
analysis ||| S:621 E:629 ||| NN
,  ||| S:629 E:631 ||| ,
we  ||| S:631 E:634 ||| PRP
predicted  ||| S:634 E:644 ||| VBD
FXN  ||| S:644 E:648 ||| NNP
was  ||| S:648 E:652 ||| VBD
the  ||| S:652 E:656 ||| DT
target  ||| S:656 E:663 ||| NN
gene  ||| S:663 E:668 ||| NN
of  ||| S:668 E:671 ||| IN
miRNA-145  ||| S:671 E:681 ||| NNP
and  ||| S:681 E:685 ||| CC
miRNA-182 ||| S:685 E:694 ||| NNP
.  ||| S:694 E:696 ||| .
Through  ||| S:696 E:704 ||| IN
real-time  ||| S:704 E:714 ||| JJ
PCR  ||| S:714 E:718 ||| NNP
analysis  ||| S:718 E:727 ||| NN
of  ||| S:727 E:730 ||| IN
clinical  ||| S:730 E:739 ||| JJ
samples  ||| S:739 E:747 ||| NNS
and  ||| S:747 E:751 ||| CC
experiments  ||| S:751 E:763 ||| NNS
in  ||| S:763 E:766 ||| IN
cell  ||| S:766 E:771 ||| NN
lines ||| S:771 E:776 ||| NNS
,  ||| S:776 E:778 ||| ,
we  ||| S:778 E:781 ||| PRP
confirmed  ||| S:781 E:791 ||| VBD
that  ||| S:791 E:796 ||| IN
miRNA-145  ||| S:796 E:806 ||| NNP
but  ||| S:806 E:810 ||| CC
not  ||| S:810 E:814 ||| RB
miRNA-182  ||| S:814 E:824 ||| RB
directly  ||| S:824 E:833 ||| RB
binds  ||| S:833 E:839 ||| VBN
to  ||| S:839 E:842 ||| TO
the  ||| S:842 E:846 ||| DT
3 ||| S:846 E:847 ||| CD
'  ||| S:847 E:849 ||| POS
UTR  ||| S:849 E:853 ||| NNP
region  ||| S:853 E:860 ||| NN
of  ||| S:860 E:863 ||| IN
FXN  ||| S:863 E:867 ||| NNP
and  ||| S:867 E:871 ||| CC
negatively  ||| S:871 E:882 ||| RB
regulates  ||| S:882 E:892 ||| VBZ
its  ||| S:892 E:896 ||| PRP$
expression ||| S:896 E:906 ||| NN
.  ||| S:906 E:908 ||| .
We  ||| S:908 E:911 ||| PRP
further  ||| S:911 E:919 ||| RB
found  ||| S:919 E:925 ||| VBN
that  ||| S:925 E:930 ||| IN
through  ||| S:930 E:938 ||| IN
targeting  ||| S:938 E:948 ||| VBG
FXN ||| S:948 E:951 ||| NNP
,  ||| S:951 E:953 ||| ,
miRNA-145  ||| S:953 E:963 ||| NNP
regulates  ||| S:963 E:973 ||| VBZ
apoptosis  ||| S:973 E:983 ||| VBN
and  ||| S:983 E:987 ||| CC
mitochondrial  ||| S:987 E:1001 ||| JJ
function ||| S:1001 E:1009 ||| NN
.  ||| S:1009 E:1011 ||| .
In  ||| S:1011 E:1014 ||| IN
general ||| S:1014 E:1021 ||| JJ
,  ||| S:1021 E:1023 ||| ,
our  ||| S:1023 E:1027 ||| PRP$
study  ||| S:1027 E:1033 ||| NN
confirmed  ||| S:1033 E:1043 ||| VBD
the  ||| S:1043 E:1047 ||| DT
differentially  ||| S:1047 E:1062 ||| NN
expressed  ||| S:1062 E:1072 ||| VBD
FXN  ||| S:1072 E:1076 ||| NNP
regulates  ||| S:1076 E:1086 ||| VBZ
the  ||| S:1086 E:1090 ||| DT
development  ||| S:1090 E:1102 ||| NN
of  ||| S:1102 E:1105 ||| IN
CHD  ||| S:1105 E:1109 ||| NNP
and  ||| S:1109 E:1113 ||| CC
the  ||| S:1113 E:1117 ||| DT
differential  ||| S:1117 E:1130 ||| JJ
expression  ||| S:1130 E:1141 ||| NN
was  ||| S:1141 E:1145 ||| VBD
under  ||| S:1145 E:1151 ||| IN
the  ||| S:1151 E:1155 ||| DT
control  ||| S:1155 E:1163 ||| NN
of  ||| S:1163 E:1166 ||| IN
miRNA-145 ||| S:1166 E:1175 ||| CD
.  ||| S:1175 E:1177 ||| .
These  ||| S:1177 E:1183 ||| DT
results  ||| S:1183 E:1191 ||| NNS
might  ||| S:1191 E:1197 ||| MD
provide  ||| S:1197 E:1205 ||| VB
new  ||| S:1205 E:1209 ||| JJ
insight  ||| S:1209 E:1217 ||| NN
into  ||| S:1217 E:1222 ||| IN
the  ||| S:1222 E:1226 ||| DT
understanding  ||| S:1226 E:1240 ||| NN
of  ||| S:1240 E:1243 ||| IN
the  ||| S:1243 E:1247 ||| DT
CHD  ||| S:1247 E:1251 ||| NNP
pathogenesis  ||| S:1251 E:1264 ||| NN
and  ||| S:1264 E:1268 ||| CC
may  ||| S:1268 E:1272 ||| MD
facilitate  ||| S:1272 E:1283 ||| VB
further  ||| S:1283 E:1291 ||| RBR
therapeutic  ||| S:1291 E:1303 ||| JJ
studies ||| S:1303 E:1310 ||| NNS
.  ||| S:1310 E:1312 ||| .
